1. Short title This Act may be cited as the Pharmacy Benefit Manager Accountability Study Act of 2019 . 2. Study by Comptroller General of United States (a) In general The Comptroller General of the United States shall, in consultation with appropriate stakeholders, conduct a study on the role of pharmacy benefit managers with respect to federally facilitated Exchanges operated pursuant to section 1321(c) of the Patient Protection and Affordable Care Act ( 42 U.S.C. 18041(c) ). (b) Permissible examination In conducting the study required under subsection (a), the Comptroller General may examine various qualitative and quantitative aspects of the role of pharmacy benefit managers with respect to federally facilitated Exchanges described in such subsection, such as the following: (1) The role that pharmacy benefit managers play in the pharmaceutical supply chain of such Exchanges. (2) The state of competition among pharmacy benefit managers on such Exchanges, including the market share for the Nation’s largest pharmacy benefit managers. (3) The use of rebates and fees by pharmacy benefit managers with respect to such Exchanges, including— (A) the extent to which rebates are passed on to qualified health plans offered on such Exchanges and whether such rebates are passed on to individuals enrolled in such plans; (B) the extent to which rebates are kept by such pharmacy benefit managers